MedTrace Logo

Microencapsulated Pomegranate Juice as Anti-Hypertensive

NCT07017296 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-12

No results posted yet for this study

Summary

Introduction: Hypertension is a significant risk factor for cardiovascular disease (CVD). Pomegranate is a fruit rich in polyphenols that exerts an antihypertensive effect. Objective: The present work evaluated microencapsulated pomegranate juice (MPJ) as an anti-hypertensive in patients with mild hypertension. Materials and Methods: The content of phenols, flavonoids, anthocyanins, and antioxidant activity in fresh pomegranate juice (FPJ) and MPJ was determined. Subsequently, the postprandial anti-hypertensive effect was evaluated in recruited participants who consumed approximately 480 kcal breakfast. Four experimental groups with five participants each were evaluated: FPJ, 150 mL fresh juice; MPJ, 20 g microencapsulated pomegranate juice; the participant's usual drug (AH); and 150 mL water (W) with breakfast. Each participant's blood pressure (BP) was measured before and after breakfast at 30, 60, 90, and 120-min. Changes in BP values were evaluated as a function of time using generalized linear models.

Conditions

  • Clinical Trial

Interventions

OTHER

Placebo

150 mL of water during the breakfast

DRUG

Positive control

Normal antihypertensive in 150 ml of water during the breakfast

DIETARY_SUPPLEMENT

Active comparator

20 g microencapsulated pomegranate juice in 150 mL water

DIETARY_SUPPLEMENT

Control

150 mL fresh pomegranate juice

Sponsors & Collaborators

  • Instituto Nacional de Cardiologia Ignacio Chavez

    collaborator OTHER

  • Universidad Nacional Autonoma de Mexico

    collaborator OTHER

  • Universidad Autónoma del Estado de Hidalgo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2024-12-31
Completion
2025-05-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07017296 on ClinicalTrials.gov